Journal Published Online: 01 January 1975
Volume 20, Issue 1

Carisoprodol-Related Death in a Child

CODEN: JFSCAS

Abstract

Carisoprodol (N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate), a congener of meprobramate, is recommended by its manufacturers as a centrally acting musculoskeletal relaxant with mild anticholinergic, antipyretic, and analgesic properties. Many authorities maintain that the beneficial effects of carisoprodol noted in the treatment of patients with muscle spasm of local origin are related more to modification of central pain perception than they are to muscle relaxant properties [1,2]. Drowsiness, vertigo, weakness, and lassitude have accompanied carisoprodol therapy, but these adverse effects occur infrequently in adults who are taking recommended dosages of 250 or 350 mg four times daily [3].

Author Information

Adams, HR
Toxicology and Pharmacology Laboratory, Department of Clinical Pathology, Scott and White Clinic, Temple, Texas
Kerzee, T
Scott and White Clinic, Temple, Texas
Morehead, CD
Schering Corp., Bloomfield, N.J.
Pages: 3
Price: $25.00
Related
Reprints and Permissions
Reprints and copyright permissions can be requested through the
Copyright Clearance Center
Details
Stock #: JFS10259J
ISSN: 0022-1198
DOI: 10.1520/JFS10259J